InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com began coverage on shares of InspireMD (NYSE:NSPR) in a research report issued on Saturday. The firm set a “sell” rating on the stock.

Several other research analysts have also recently issued reports on NSPR. Piper Sandler reaffirmed an “overweight” rating and issued a $4.50 price target on shares of InspireMD in a report on Tuesday, September 17th. Lake Street Capital assumed coverage on InspireMD in a research report on Wednesday, December 11th. They issued a “buy” rating and a $5.00 price target for the company.

InspireMD Price Performance

NSPR opened at $2.69 on Friday. The business has a 50 day moving average price of $2.73 and a two-hundred day moving average price of $2.70. The company has a market capitalization of $70.17 million, a price-to-earnings ratio of -3.59 and a beta of 0.98. InspireMD has a 1-year low of $1.81 and a 1-year high of $3.42.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. InspireMD had a negative return on equity of 69.42% and a negative net margin of 413.96%. The business had revenue of $1.81 million during the quarter, compared to analysts’ expectations of $1.74 million. During the same quarter last year, the business posted ($0.15) earnings per share. Equities analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Institutional Trading of InspireMD

A hedge fund recently bought a new stake in InspireMD stock. Affiance Financial LLC purchased a new stake in shares of InspireMD, Inc. (NYSE:NSPR) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 183,746 shares of the company’s stock, valued at approximately $492,000. Affiance Financial LLC owned 0.74% of InspireMD at the end of the most recent quarter. Institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.